ofloxacin and roxithromycin

PreclinicalSmall molecule

ofloxacin and roxithromycin is one of 4 small molecule programs targeting Reactive Arthritis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Reactive ArthritisActive, not recruiting

Reactive ArthritisPreclinical

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Reactive Arthritis

#DrugCompanyPhaseTrials

Rifadin

Sanofi

Approved

—2

Zithromax

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—3

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—4

ofloxacin and roxithromycin

UUniversity of Helsinki

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Reactive Arthritis1 trial

Study of Long-Term Antibiotic Treatment in Reactive Arthritis

Completed·UUniversity of Helsinki·N/A·NCT00621387·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ofloxacin and roxithromycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ofloxacin and roxithromycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ofloxacin and roxithromycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Helsinki company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Helsinki

ofloxacin and roxithromycin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Reactive Arthritis1 trial

References

Drug Info

Quick Facts

Related News